Compare DexCom, Inc. (DXCM) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Paycom Software Inc — how do they compare? DexCom, Inc. trades at $77.67 (market cap $28.06B), while Paycom Software Inc trades at $148.31 (market cap $6.75B). The key difference: DexCom, Inc. is far larger — about 4.2× Paycom Software Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PAYC | |
|---|---|---|
Market Cap | $28.06B | $6.75B |
Sector | Health | Technology |
52-Week High | $89.53 | $238.80 |
52-Week Low | $54.84 | $113.59 |
Enterprise Value | $27.03B | $7.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Paycom Software (PAYC) trades at $148.20, up 3.15% today, with a bullish technical signal from moving averages and a consensus analyst price target of $151.00. The company reported strong Q1 2026 earnings of $3.15 per share, beating estimates, and maintains robust profitability with a 22.44% net income margin. Recent developments include the launch of an asset management tool and new board appointments, highlighting ongoing innovation and governance strength.
The outlook for PAYC is positive, supported by consistent revenue growth, high margins, and strategic product expansions. Key risks include competitive pressures in HCM software and execution challenges. With a balanced analyst rating split and solid institutional backing, the stock presents a moderate growth opportunity, though investors should monitor upcoming Q2 2026 earnings for further direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
